Peptide receptor targeting in cancer: The somatostatin paradigm

International Journal of Peptides

Volumn 2013, Issue , 2013, Pages

  Barbieri, Federica ^a   Bajetto, Adriana ^a   Pattarozzi, Alessandra ^a   Gatti, Monica ^a   Würth, Roberto ^a   Thellung, Stefano ^a   Corsaro, Alessandro ^a   Villa, Valentina ^a   Nizzari, Mario ^a   Florio, Tullio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BIM 23 A757; BIM 23 A761; BIM 23 A799; BIM 23120; BIM 23190; BIM 23206; BIM 23268; BIM 23704; BIM 23745; BIM 23760; BIM 23926; BN 81658; CST 14; CST 17; CYN 154806; KE 108; L 779976; L 796778; L 797591; L 803087; L 817818; OCTREOTIDE; ODN 8; PASIREOTIDE; RECEPTOR BLOCKING AGENT; SEGLITIDE; SOMATOPRIM; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SST 14; SST 28; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPREOTIDE;

AMINO ACID COMPOSITION; BINDING AFFINITY; BREAST CANCER; DIGESTIVE SYSTEM CANCER; DIMERIZATION; GLIOBLASTOMA; HUMAN; HYPOPHYSIS ADENOMA; IC 50; NONHUMAN; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; SMALL CELL CARCINOMA; TUMOR CELL;

EID: 84879191836     PISSN: 16879767     EISSN: 16879775     Source Type: Journal    
DOI: 10.1155/2013/926295     Document Type: Review

References (222)

1. Patel Y. C., Somatostatin and its receptor family. Frontiers in Neuroendocrinology 1999 20 3 157 198 2-s2.0-0032780823 10.1006/frne.1999.0183 (Pubitemid 29362641)
2. Epelbaum J., Guillou J. L., Gastambide F., Hoyer D., Duron E., Viollet C., Somatostatin, Alzheimer's disease and cognition: an old story coming of age? Progress in Neurobiology 2009 89 2 153 161 2-s2.0-70249110364 10.1016/j.pneurobio.2009.07.002
3. Kharmate G., Rajput P. S., Watt H. L., Somvanshi R. K., Chaudhari N., Qiu X., Kumar U., Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling. Biochimica et Biophysica Acta 2011 1813 6 1172 1189 2-s2.0-79955646925 10.1016/j.bbamcr.2011.03.006
4. Kumar U., Cross-talk and modulation of signaling between somatostatin and growth factor receptors. Endocrine 2011 40 2 168 180
5. Florio T., Schettini G., Multiple intracellular effecters modulate physiological functions of the cloned somatostatin receptors. Journal of Molecular Endocrinology 1996 17 2 89 100 2-s2.0-0029658454 10.1677/jme.0.0170089 (Pubitemid 26379310)
6. Córdoba-Chacón J., Gahete M. D., Castaño J. P., Kineman R. D., Luque R. M., Somatostatin and its receptors contribute in a tissue-specific manner to the sex-dependent metabolic (fed/fasting) control of growth hormone axis in mice. American Journal of Physiology 2011 300 1 E46 E54 2-s2.0-78650788052 10.1152/ajpendo.00514.2010
7. Durán-Prado M., Gahete M. D., Martínez-Fuentes A. J., Luque R. M., Quintero A., Webb S. M., Benito-López P., Leal A., Schulz S., Gracia-Navarro F., Malagón M. M., Castaño J. P., Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. The Journal of Clinical Endocrinology and Metabolism 2009 94 7 2634 2643 2-s2.0-67650245551 10.1210/jc.2008-2564
8. Weckbecker G., Lewis I., Albert R., Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nature Reviews Drug Discovery 2003 2 12 999 1017 (Pubitemid 37540581)
9. de Lecea L., Ruiz-Lozano P., Danielson P. E., Peelle-Kirley J., Foye P. E., Frankel W. N., Sutcliffe J. G., Cloning, mRNA expression, and chromosomal mapping of mouse and human preprocortistatin. Genomics 1997 42 3 499 506 2-s2.0-0031570705 10.1006/geno.1997.4763 (Pubitemid 27287393)
10. Castaño J. P., Ghigo E., Kineman R. D., de Lecea L., Malagón M. M., Vaudry H., Somatostatin, cortistatin and their receptors in health and disease. Foreword. Molecular and Cellular Endocrinology 2008 286 1-2 1 2 2-s2.0-67650353936
11. de Lecea L., Cortistatin-functions in the central nervous system. Molecular and Cellular Endocrinology 2008 286 1-2 88 95 2-s2.0-43549085498 10.1016/j.mce.2007.12.014
12. Robas N., Mead E., Fidock M., MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. The Journal of Biological Chemistry 2003 278 45 44400 44404 2-s2.0-0242666360 10.1074/jbc.M302456200 (Pubitemid 37377189)
13. Siehler S., Nunn C., Hannon J., Feuerbach D., Hoyer D., Pharmacological profile of somatostatin and cortistatin receptors. Molecular and Cellular Endocrinology 2008 286 1-2 26 34 2-s2.0-43549087397 10.1016/j.mce.2007.12.007
14. Guillermet-Guibert J., Lahlou H., Cordelier P., Bousquet C., Pyronnet S., Susini C., Physiology of somatostatin receptors. Journal of Endocrinological Investigation 2005 28 supplement 11 5 9 2-s2.0-33745006404
15. Florio T., Thellung S., Schettini G., Intracellular transducing mechanisms coupled to brain somatostatin receptors. Pharmacological Research 1996 33 6 297 305 2-s2.0-0030174997 10.1006/phrs.1996.0042 (Pubitemid 26413589)
16. 1) modulates the release of somatostatin in the nucleus accumbens of the rat. Neuropharmacology 2004 47 4 612 618 2-s2.0-4544300184 10.1016/j.neuropharm.2004.06.008 (Pubitemid 39221783)
17. Schettini G., Florio T., Magri G., Grimaldi M., Meucci O., Landolfi E., Marino A., Somatostatin and SMS 201-995 reverse the impairment of cognitive functions induced by cysteamine depletion of brain somatostatin. European Journal of Pharmacology 1988 151 3 399 407 2-s2.0-0023742878 10.1016/0014-2999(88)90536-5
18. Vecsei L., Widerlov E., Effects of intracerebroventricularly administered somatostatin on passive avoidance, shuttle-box behaviour and open-field activity in rats. Neuropeptides 1988 12 4 237 242 2-s2.0-0023745220 (Pubitemid 18262170)
19. Florio T., Ventra C., Postiglione A., Schettini G., Age-related alterations of somatostatin gene expression in different rat brain areas. Brain Research 1991 557 1-2 64 68 2-s2.0-0025779212
20. Grimaldi M., Florio T., Schettini G., Somatostatin inhibits interleukin 6 release from rat cortical type I astrocytes via the inhibition of adenylyl cyclase. Biochemical and Biophysical Research Communications 1997 235 1 242 248 2-s2.0-0031560945 10.1006/bbrc.1997.6513 (Pubitemid 27302719)
21. Pintér E., Helyes Z., Szolcsanyi J., Inhibitory effect of somatostatin on inflammation and nociception. Pharmacology and Therapeutics 2006 112 2 440 456 2-s2.0-33749443206 10.1016/j.pharmthera.2006.04.010 (Pubitemid 44508773)
22. Ferone D., van Hagen P. M., Pivonello R., Colao A., Lamberts S. W. J., Hofland L. J., Physiological and pathophysiological role of somatostatin receptors in the human thymus. European Journal of Endocrinology 2000 143 supplement 1 S27 S34 2-s2.0-0033781311
23. Ferone D., Boschetti M., Resmini E., Giusti M., Albanese V., Goglia U., Albertelli M., Vera L., Bianchi F., Minuto F., Neuroendocrine-immune interactions: the role of cortistatin/somatostatin system. Annals of the New York Academy of Sciences 2006 1069 129 144 2-s2.0-33745607575 10.1196/annals.1351.011 (Pubitemid 43989856)
24. Ameri P., Ferone D., Diffuse endocrine system, neuroendocrine tumors and immunity: what's new? Neuroendocrinology 2012 95 4 267 276
25. Corleto V. D., Somatostatin and the gastrointestinal tract. Current Opinion in Endocrinology, Diabetes and Obesity 2010 17 1 63 68 2-s2.0-75149118251 10.1097/MED.0b013e32833463ed
26. Ben-Shlomo A., Shlomo S. M., Pituitary somatostatin receptor signaling. Trends in Endocrinology and Metabolism 2010 21 3 123 133 2-s2.0-77949314882 10.1016/j.tem.2009.12.003
27. Florio T., Rim C., Hershberger R. E., Loda M., Stork P. J. S., The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells. Molecular Endocrinology 1994 8 10 1289 1297 2-s2.0-0028134705 10.1210/me.8.10.1289 (Pubitemid 24335072)
28. Florio T., Thellung S., Arena S., Corsaro A., Bajetto A., Schettini G., Stork P. J. S., Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2. Journal of Physiology Paris 2000 94 3-4 239 250 2-s2.0-0033728783 10.1016/S0928-4257(00)00214-X
29. Hershberger R. E., Newman B. L., Florio T., Bunzow J., Civelli O., Li X. J., Forte M., Stork P. J. S., The somatostatin receptors SSTR1 and SSTR2 are coupled to inhibition of adenylyl cyclase in Chinese hamster ovary cells via pertussis toxin-sensitive pathways. Endocrinology 1994 134 3 1277 1285 2-s2.0-0028176917 10.1210/en.134.3.1277
30. Meucci O., Landolfi E., Scorziello A., Grimaldi M., Ventra C., Florio T., Avallone A., Schettini G., Dopamine and somatostatin inhibition of prolactin secretion from MMQ pituitary cells: role of adenosine triphosphate-sensitive potassium channels. Endocrinology 1992 131 4 1942 1947 2-s2.0-0026744458 10.1210/en.131.4.1942
31. Schettini G., Florio T., Meucci O., Landolfi E., Grimaldi M., Ventra C., Marino A., Somatostatin inhibition of adenylate cyclase activity in different brain areas. Brain Research 1989 492 1-2 65 71 2-s2.0-0024333173 (Pubitemid 19184538)
32. Schettini G., Florio T., Meucci O., Landolfi E., Lombardi G., Marino A., Somatostatin inhibition of anterior pituitary adenylate cyclase activity: different sensitivity between male and female rats. Brain Research 1988 439 1-2 322 329 2-s2.0-0023839135 (Pubitemid 18065718)
33. Florio T., Yao H., Carey K. D., Dillon T. J., Stork P. J. S., Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Molecular Endocrinology 1999 13 1 24 37 2-s2.0-0002709117 10.1210/me.13.1.24 (Pubitemid 29022277)
34. Viana F., Hille B., Modulation of high voltage-activated calcium channels by somatostatin in acutely isolated rat amygdaloid neurons. The Journal of Neuroscience 1996 16 19 6000 6011 2-s2.0-0029812770 (Pubitemid 26313976)
35. Kreienkamp H. J., Hönck H. H., Richter D., Coupling of rat somatostatin receptor subtypes to a G-protein gated inwardly rectifying potassium channel (GIRK1). FEBS Letters 1997 419 1 92 94 2-s2.0-0345055798 10.1016/S0014-5793(97)01437-3 (Pubitemid 28011223)
36. Buscail L., Delesque N., Esteve J. P., Saint-Laurent N., Prats H., Clerc P., Robberecht P., Bell G. I., Liebow C., Schally A. V., Vaysse N., Susini C., Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proceedings of the National Academy of Sciences of the United States of America 1994 91 6 2315 2319 2-s2.0-0028203634 (Pubitemid 24092094)
37. Buscail L., Estève J. P., Saint-Laurent N., Bertrand V., Reisine T., O'Carroll A. M., Bell G. I., Schally A. V., Vaysse N., Susini C., Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proceedings of the National Academy of Sciences of the United States of America 1995 92 5 1580 1584 2-s2.0-0028929754 10.1073/pnas.92.5.1580
38. Florio T., Scorziello A., Fattore M., D'Alto V., Salzano S., Rossi G., Berlingieri M. T., Fusco A., Schettini G., Somatostatin inhibits PC C13 thyroid cell proliferation through the modulation of phosphotyrosine phosphatase activity: impairment of the somatostatinergic effects by stable expression of eia viral oncogene. The Journal of Biological Chemistry 1996 271 11 6129 6136 2-s2.0-0029939159
39. Seino S., Somatostatin receptor subtype SSTR2 mediates the inhibition of high-voltage-activated calcium channels by somatostatin and its analogue SMS 201-995. FEBS Letters 1994 355 2 117 120 2-s2.0-0027943354 10.1016/0014-5793(94) 01159-1 (Pubitemid 24355100)
40. Reardon D. B., Dent P., Wood S. L., Kong T., Sturgill T. W., Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed nih 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness. Molecular Endocrinology 1997 11 8 1062 1069 2-s2.0-0030949012 10.1210/me.11.8.1062 (Pubitemid 27278829)
41. 2+ currents in rat insulinoma 1046-38 cells. FEBS Letters 1998 425 1 137 140 2-s2.0-0032549635 10.1016/S0014-5793(98)00221-X (Pubitemid 28149757)
42. + channels through protein dephosphorylation. Nature 1991 351 6327 570 573 2-s2.0-0025829064 10.1038/351570a0 (Pubitemid 21896642)
43. Yoshitomi H., Fujii Y., Miyazaki M., Nakajima N., Inagaki N., Seino S., Involvement of MAP kinase and c-fos signaling in the inhibition of cell growth by somatostatin. American Journal of Physiology 1997 272 5 E769 E774 2-s2.0-0030922670
44. Florio T., Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Frontiers in Bioscience 2008 13 3 822 840 2-s2.0-38449109564
45. Møller L. N., Stidsen C. E., Hartmann B., Holst J. J., Somatostatin receptors. Biochimica et Biophysica Acta 2003 1616 1 1 84 2-s2.0-0142090450 10.1016/S0005-2736(03)00235-9 (Pubitemid 37272115)
46. Durán-Prado M., Malagón M. M., Gracia-Navarro F., Castaño J. P., Dimerization of G protein-coupled receptors: new avenues for somatostatin receptor signalling, control and functioning. Molecular and Cellular Endocrinology 2008 286 1-2 63 68 2-s2.0-43749115484 10.1016/j.mce.2007.12.006
47. Rocheville M., Lange D. C., Kumar U., Sasi R., Patel R. C., Patel Y. C., Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. The Journal of Biological Chemistry 2000 275 11 7862 7869 2-s2.0-0034677745 10.1074/jbc.275.11.7862 (Pubitemid 30159693)
48. Baragli A., Alturaihi H., Watt H. L., Abdallah A., Kumar U., Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2. Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cellular Signalling 2007 19 11 2304 2316 2-s2.0-34548450155 10.1016/j.cellsig. 2007.07.007 (Pubitemid 47361686)
49. Rocheville M., Lange D. C., Kumar U., Patel S. C., Patel R. C., Patel Y. C., Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000 288 5463 154 157 2-s2.0-0034616021 10.1126/science.288.5463.154 (Pubitemid 30203051)
50. Grant M., Alturaihi H., Jaquet P., Collier B., Kumar U., Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Molecular Endocrinology 2008 22 10 2278 2292 2-s2.0-52949103344 10.1210/me.2007-0334
51. Grant M., Patel R. C., Kumar U., The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. The Journal of Biological Chemistry 2004 279 37 38636 38643 2-s2.0-4644253963 10.1074/jbc.M406276200 (Pubitemid 39296019)
52. War S. A., Somvanshi R. K., Kumar U., Somatostatin receptor-3 mediated intracellular signaling and apoptosis is regulated by its cytoplasmic terminal. Biochimica et Biophysica Acta 2011 1813 3 390 402 2-s2.0-78951479962 10.1016/j.bbamcr.2010.12.015
53. Florio T., Barbieri F., Spaziante R., Zona G., Hofland L. J., Van Koetsveld P. M., Feelders R. A., Stella G. K., Theodoropoulou M., Culler M. D., Dong J., Taylor J. E., Moreau J. P., Saveanu A., Gunz G., Dufour H., Jaquet P., Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocrine-Related Cancer 2008 15 2 583 596 2-s2.0-45849121042 10.1677/ERC-07-0271 (Pubitemid 351880845)
54. Hofland L. J., Feelders R. A., de Herder W. W., Lamberts S. W. J., Pituitary tumours: the sst/D2 receptors as molecular targets. Molecular and Cellular Endocrinology 2010 326 1-2 89 98 2-s2.0-77955329988 10.1016/j.mce.2010.04.020
55. Arvigo M., Gatto F., Ruscica M., Ameri P., Dozio E., Albertelli M., Culler M. D., Motta M., Minuto F., Magni P., Ferone D., Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines. Journal of Endocrinology 2010 207 3 309 317 2-s2.0-78650042035 10.1677/JOE-10-0342
56. Watt H. L., Kharmate G. D., Kumar U., Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells. Cellular Signalling 2009 21 3 428 439 2-s2.0-58249143438 10.1016/j.cellsig.2008. 11.012
57. Pan M. G., Florio T., Stork P. J. S., G protein activation of a hormone-stimulated phosphatase in human tumor cells. Science 1992 256 5060 1215 1217 2-s2.0-0026682699
58. Csaba Z., Peineau S., Dournaud P., Molecular mechanisms of somatostatin receptor trafficking. Journal of Molecular Endocrinology 2012 48 1 R1 R12
59. Tulipano G., Stumm R., Pfeiffer M., Kreienkamp H. J., Höllt V., Schulz S., Differential β -arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. The Journal of Biological Chemistry 2004 279 20 21374 21382 2-s2.0-2442705543 10.1074/jbc.M313522200 (Pubitemid 38656546)
60. Tulipano G., Schulz S., Novel insights in somatostatin receptor physiology. European Journal of Endocrinology 2007 156 supplement 1 S3 S11 2-s2.0-34249035476 10.1530/eje.1.02354 (Pubitemid 46797838)
61. Jacobs S., Schulz S., Intracellular trafficking of somatostatin receptors. Molecular and Cellular Endocrinology 2008 286 1-2 58 62 2-s2.0-43549108765 10.1016/j.mce.2007.10.005 (Pubitemid 351680240)
62. Reubi J. C., Waser B., Cescato R., Gloor B., Stettler C., Christ E., Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients. The Journal of Clinical Endocrinology and Metabolism 2010 95 5 2343 2350 2-s2.0-77952756362 10.1210/jc.2009-2487
63. Lesche S., Lehmann D., Nagel F., Schmid H. A., Schulz S., Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. The Journal of Clinical Endocrinology and Metabolism 2009 94 2 654 661 2-s2.0-59749083610 10.1210/jc.2008-1919
64. 2 receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model. European Journal of Pharmacology 2010 644 1-3 257 262 2-s2.0-77955767984 10.1016/j.ejphar.2010.07. 005
65. Kliewer A., Mann A., Petrich A., A transplantable phosphorylation probe for direct assessment of G protein-coupled receptor activation. PloS ONE 2012 7 6 e39458
66. Cozzi R., Attanasio R., Octreotide long-acting repeatable for acromegaly. Expert Review of Clinical Pharmacology 2012 5 2 125 143
67. Mazziotti G., Giustina A., Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 2010 13 1 60 67 2-s2.0-77949273975 10.1007/s11102-009-0169-z
68. Rohrer S. P., Birzin E. T., Mosley R. T., Berk S. C., Hutchins S. M., Shen D. M., Xiong Y., Hayes E. C., Parmar R. M., Foor F., Mitra S. W., Degrado S. J., Shu M., Klopp J. M., Cai S. J., Blake A., Chan W. W. S., Pasternak A., Yang L., Patchett A. A., Smith R. G., Chapman K. T., Schaeffer J. M., Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998 282 5389 737 740 2-s2.0-0032561511 10.1126/science.282.5389.737 (Pubitemid 28489384)
69. Barbieri F., Pattarozzi A., Gatti M., Porcile C., Bajetto A., Ferrari A., Culler M. D., Florio T., Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase- η -dependent inhibition of extracellularly regulated kinase-1/2. Endocrinology 2008 149 9 4736 4746 2-s2.0-50449108845 10.1210/en.2007-1762
70. Barbieri F., Pattarozzi A., Gatti M., Aiello C., Quintero A., Lunardi G., Bajetto A., Ferrari A., Culler M. D., Florio T., Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. American Journal of Physiology 2009 297 5 E1078 E1088 2-s2.0-70350451243 10.1152/ajpendo.00292.2009
71. Cervia D., Langenegger D., Schuepbach E., Cammalleri M., Schoeffter P., Schmid H. A., Bagnoli P., Hoyer D., Binding and functional properties of the novel somatostatin analogue KE 108 at native mouse somatostatin receptors. Neuropharmacology 2005 48 6 881 893 2-s2.0-16844366812 10.1016/j.neuropharm. 2004.12.019 (Pubitemid 40489043)
72. Plockinger U., Hoffmann U., Geese M., DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in octreotide non-responsive tumours. European Journal of Endocrinology 2012 166 2 223 234
73. Schmid H. A., Pasireotide (SOM230): development, mechanism of action and potential applications. Molecular and Cellular Endocrinology 2008 286 1-2 69 74 2-s2.0-43549111835 10.1016/j.mce.2007.09.006 (Pubitemid 351680237)
74. Ben-Shlomo A., Schmid H., Wawrowsky K., Pichurin O., Hubina E., Chesnokova V., Liu N. A., Culler M., Melmed S., Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. The Journal of Clinical Endocrinology and Metabolism 2009 94 11 4342 4350 2-s2.0-70449127649 10.1210/jc.2009-1311
75. Ben-Shlomo A., Melmed S., Pasireotide-a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. IDrugs 2007 10 12 885 895 2-s2.0-36549070665 (Pubitemid 350179091)
76. Colao A., Petersenn S., Newell-Price J., A 12-month phase 3 study of pasireotide in Cushing's disease. The New England Journal of Medicine 2012 366 10 914 924
77. Saveanu A., Gunz G., Guillen S., Dufour H., Culler M. D., Jaquet P., Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 2006 83 3-4 258 263 2-s2.0-33750090081 10.1159/000095536 (Pubitemid 44578880)
78. Shimon I., Rubinek T., Hadani M., Alhadef N., PTR-3173 (Somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion. Journal of Endocrinological Investigation 2004 27 8 721 727 2-s2.0-10244235366 (Pubitemid 39619057)
79. Elekes K., Helyes Z., Kereskai L., Inhibitory effects of synthetic somatostatin receptor subtype 4 agonists on acute and chronic airway inflammation and hyperreactivity in the mouse. European Journal of Pharmacology 2008 578 2-3 313 322 2-s2.0-37448999132 10.1016/j.ejphar.2007.09.033
80. Szokolóczi O., Schwab R., Peták I., TT232, a novel signal transduction inhibitory compound in the therapy of cancer and inflammatory diseases. Journal of Receptors and Signal Transduction 2005 25 4-6 217 235 2-s2.0-30344440802 10.1080/10799890500464621 (Pubitemid 43068277)
81. Szolcsanyi J., Bölcskei K., Szabó A., Pintér E., Petho G., Elekes K., Börzsei R., Almási R., Szuts T., Kéri G., Helyes Z., Analgesic effect of TT-232, a heptapeptide somatostatin analogue, in acute pain models of the rat and the mouse and in streptozotocin-induced diabetic mechanical allodynia. European Journal of Pharmacology 2004 498 1-3 103 109 2-s2.0-4444223948 10.1016/j.ejphar.2004.07.085 (Pubitemid 39208067)
82. Ramón R., Martín-Gago P., Verdaguer X., Macias M. J., Martin-Malpartida P., Fernández-Carneado J., Gomez-Caminals M., Ponsati B., López-Ruiz P., Cortés M. A., Colás B., Riera A., SSTR1- and SSTR3-selective somatostatin analogues. ChemBioChem 2011 12 4 625 632 2-s2.0-79952023818 10.1002/cbic.201000597
83. 3 selectivity. Journal of Medicinal Chemistry 2001 44 18 2990 3000 2-s2.0-0035974773 10.1021/jm0108449 (Pubitemid 32879128)
84. Gatto F., Hofland L. J., The role of somatostatin and dopamine D2 receptors in endocrine tumors. Endocrine-Related Cancer 2011 18 6 R233 R251
85. Saveanu A., Lavaque E., Gunz G., Barlier A., Kim S., Taylor J. E., Culler M. D., Enjalbert A., Jaquet P., Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. The Journal of Clinical Endocrinology and Metabolism 2002 87 12 5545 5552 2-s2.0-0036929913 10.1210/jc.2002-020934 (Pubitemid 36034358)
86. Ferone D., Arvigo M., Semino C., Jaquet P., Saveanu A., Taylor J. E., Moreau J. P., Culler M. D., Albertelli M., Minuto F., Barreca A., Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation. American Journal of Physiology 2005 289 6 E1044 E1050 2-s2.0-33644664300 10.1152/ajpendo.00209.2005 (Pubitemid 43671055)
87. Culler M. D., Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors. Hormone and Metabolic Research 2011 43 12 854 857
88. Lamberts S. W. J., Bakker W. H., Reubi J. C., Krenning E. P., Somatostatin-receptor imaging in the localization of endocrine tumors. The New England Journal of Medicine 1990 323 18 1246 1249 2-s2.0-0025173459 (Pubitemid 20366530)
89. Modlin I. M., Moss S. F., Oberg K., Padbury R., Hicks R. J., Gustafsson B. I., Wright N. A., Kidd M., Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. Medical Journal of Australia 2010 193 1 46 52 2-s2.0-77955614650
90. Kwekkeboom D. J., Kam B. L., Van Essen M., Teunissen J. J. M., Van Eijck C. H. J., Valkema R., De Jong M., De Herder W. W., Krenning E. P., Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocrine-Related Cancer 2010 17 1 R53 R73 2-s2.0-77449132297 10.1677/ERC-09-0078
91. 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 2007 34 10 1617 1626 2-s2.0-34748835270 10.1007/s00259-007- 0450-1 (Pubitemid 47476920)
92. Frilling A., Sotiropoulos G. C., Li J., Kornasiewicz O., Plöckinger U., Multimodal management of neuroendocrine liver metastases. HPB 2010 12 6 361 379 2-s2.0-77956903739 10.1111/j.1477-2574.2010.00175.x
93. 90Y- labeled somatostatin analogs. Journal of Nuclear Medicine 2005 46 1 2-s2.0-14844350129
94. 90Y-DOTA]-TOC in metastasized neuroendocrine cancers. Journal of Clinical Oncology 2011 29 17 2416 2423 2-s2.0-79959208861 10.1200/JCO.2010.33.7873
95. 177Lu-DOTA]-TOC in neuroendocrine cancers. Journal of Clinical Oncology 2012 30 10 1100 1106
96. 5 receptors: effects of somatostatin agonists and antagonists. Journal of Nuclear Medicine 2006 47 3 502 511 2-s2.0-33646005541 (Pubitemid 46768493)
97. Ginj M., Zhang H., Waser B., Cescato R., Wild D., Wang X., Erchegyi J., Rivier J., Mäcke H. R., Reubi J. C., Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proceedings of the National Academy of Sciences of the United States of America 2006 103 44 16436 16441 2-s2.0-33750823665 10.1073/pnas.0607761103 (Pubitemid 44715214)
98. Wang X., Fani M., Schulz S., Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging 2012 39 12 1876 1885
99. 68Ga-somatostatin antagonists: the chelate makes the difference. Journal of Nuclear Medicine 2011 52 7 1110 1118 2-s2.0-79960323194 10.2967/jnumed.111.087999
100. Wild D., Fani M., Behe M., First clinical evidence that imaging with somatostatin receptor antagonists is feasible. Journal of Nuclear Medicine 2011 52 9 1412 1417
101. Schmidt M., Scheidhauer K., Luyken C., Voth E., Hildebrandt G., Klug N., Schicha H., Somatostatin receptor imaging in intracranial tumours. European Journal of Nuclear Medicine 1998 25 7 675 686 2-s2.0-0031869741 10.1007/s002590050269 (Pubitemid 28377029)
102. Pepe G., Moncayo R., Bombardieri E., Somatostatin receptor SPECT. European Journal of Nuclear Medicine and Molecular Imaging 2012 39 Supplement 1 S41 S51
103. de Herder W. W., Kwekkeboom D. J., Feelders R. A., van Aken M. O., Lamberts S. W. J., van der Lely A. J., Krenning E. P., Somatostatin receptor imaging for neuroendocrine tumors. Pituitary 2006 9 3 243 248 2-s2.0-33750998202 10.1007/s11102-006-0270-5 (Pubitemid 44742286)
104. Goglia U., Ferone D., Sidoti M., Spaziante R., Dadati P., Ravetti J. L., Villa G., Bodei L., Paganelli G., Minuto F., Giusti M., Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review. Pituitary 2008 11 1 93 102 2-s2.0-38649104477 10.1007/s11102-007-0038-6 (Pubitemid 351168089)
105. 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. Pituitary 2012 15 Supplement 1 57 60
106. Ambrosini V., Fani M., Fanti S., Radiopeptide imaging and therapy in Europe. Journal of Nuclear Medicine 2011 52 Supplement 2 42S 55S
107. Graham M. M., Menda Y., Radiopeptide imaging and therapy in the United States. Journal of Nuclear Medicine 2011 52 Supplement 2 56S 63S
108. Hofland L. J., Responsiveness to somatostatin analog treatment and potentials of novel somatostatin analog. Journal of endocrinological investigation 2003 26 supplement 8 8 13 2-s2.0-3543063420
109. Florio T., Arena S., Thellung S., Iuliano R., Corsaro A., Massa A., Pattarozzi A., Bajetto A., Trapasso F., Fusco A., Schettini G., The activation of the phosphotyrosine phosphatase η (r-PTP η) is responsible for the somatostatin inhibition of PC CI3 thyroid cell proliferation. Molecular Endocrinology 2001 15 10 1838 1852 2-s2.0-17944371605 10.1210/me.15.10.1838 (Pubitemid 32939313)
110. Theodoropoulou M., Zhang J., Laupheimer S., Paez-Pereda M., Erneux C., Florio T., Pagotto U., Stalla G. K., Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Research 2006 66 3 1576 1582 2-s2.0-32944477371 10.1158/0008-5472.CAN-05-1189 (Pubitemid 43259940)
111. 2 somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. The Journal of Biological Chemistry 2003 278 41 39356 39371 2-s2.0-0141925804 10.1074/jbc.M304524200 (Pubitemid 37248491)
112. 2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. The Journal of Biological Chemistry 1999 274 21 15186 15193 2-s2.0-0033591423 10.1074/jbc.274.21.15186 (Pubitemid 29265911)
113. Sharma K., Patel Y. C., Srikant C. B., Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Molecular Endocrinology 1996 10 12 1688 1696 2-s2.0-0029959644 10.1210/me.10.12.1688 (Pubitemid 26408756)
114. Srikant C. B., Shen S. H., Octapeptide somatostatin analog SMS 201-995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells. Endocrinology 1996 137 8 3461 3468 2-s2.0-0029937024 10.1210/en.137.8.3461 (Pubitemid 26250200)
115. Arena S., Pattarozzi A., Corsaro A., Schettini G., Florio T., Somatostatin receptor subtype-dependent regulation of nitric oxide release: involvement of different intracellular pathways. Molecular Endocrinology 2005 19 1 255 267 2-s2.0-11244289595 10.1210/me.2004-0280 (Pubitemid 40065974)
116. Cerovac V., Monteserin-Garcia J., Rubinfeld H., Buchfelder M., Losa M., Florio T., Paez-Pereda M., Stalla G. K., Theodoropoulou M., The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Research 2010 70 2 666 674 2-s2.0-76549120195 10.1158/0008-5472.CAN-09-2951
117. 5 somatostatin receptor activation. The Journal of Biological Chemistry 2006 281 28 19156 19171 2-s2.0-33745866896 10.1074/jbc.M602024200 (Pubitemid 44035420)
118. Thermos K., Novel signals mediating the functions of somatostatin: the emerging role of NO/cGMP. Molecular and Cellular Endocrinology 2008 286 1-2 49 57 2-s2.0-43549125007 10.1016/j.mce.2008.02.008
119. 2 somatostatin receptor growth inhibitory signaling. The FASEB Journal 2001 15 12 2300 2302 2-s2.0-0035487006
120. 2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proceedings of the National Academy of Sciences of the United States of America 2000 97 16 9180 9185 2-s2.0-0034254910 (Pubitemid 30626694)
121. Douziech N., Calvo E., Coulombe Z., Muradia G., Bastien J., Aubin R. A., Lajas A., Morisset J., Inhibitory and stimulatory effects of somatostatin on two human pancreatic cancer cell lines: a primary role for tyrosine phosphatase SHP-1. Endocrinology 1999 140 2 765 777 2-s2.0-0032934791 10.1210/en.140.2.765 (Pubitemid 29058211)
122. Thangaraju M., Sharma K., Liu D., Shen S. H., Srikant C. B., Interdependent regulation of intracellular acidification and SHP-1 in apoptosis. Cancer Research 1999 59 7 1649 1654 2-s2.0-0033119834 (Pubitemid 29160139)
123. Zapata P. D., Ropero R. M., Valencia A. M., Buscail L., López J. I., Martín-Orozco R. M., Prieto J. C., Angulo J., Susini C., López-Ruiz P., Colás B., Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1. The Journal of Clinical Endocrinology and Metabolism 2002 87 2 915 926 2-s2.0-18244402690 10.1210/jc.87.2.915 (Pubitemid 34158272)
124. Zatelli M. C., Piccin D., Tagliati F., Bottoni A., Luchin A., Uberti E. C. D., Src homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma. Endocrinology 2005 146 6 2692 2698 2-s2.0-18844395883 10.1210/en.2005-0001 (Pubitemid 40695572)
125. 2-mediated inhibitory growth signaling. The Journal of Biological Chemistry 1997 272 39 24448 24454 2-s2.0-0030813044 10.1074/jbc.272.39.24448 (Pubitemid 27418653)
126. 2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase SHP-1. The Journal of Biological Chemistry 1998 273 12 7099 7106 2-s2.0-0032549589 10.1074/jbc.273.12.7099 (Pubitemid 28160380)
127. 2 on the intracrine-regulated cell proliferation induced by the 210-amino acid fibroblast growth factor-2 isoform. Implication of JAK2. The Journal of Biological Chemistry 2003 278 23 20574 20581 2-s2.0-0038757751 10.1074/jbc.M210767200 (Pubitemid 36806355)
128. 2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation. Molecular Biology of the Cell 2003 14 9 3911 3928 2-s2.0-10744231884 10.1091/mbc.E03-02-0069 (Pubitemid 37151636)
129. Florio T., Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases. Molecular and Cellular Endocrinology 2008 286 1-2 40 48 2-s2.0-43549097557 10.1016/j.mce.2007.08.012 (Pubitemid 351680234)
130. 2 on growth factor signal cascades in human glioma cells. Molecular Brain Research 2001 87 1 12 21 2-s2.0-0035910930 10.1016/S0169-328X(00)00225-4 (Pubitemid 32167036)
131. Cattaneo M. G., Taylor J. E., Culler M. D., Nisoli E., Vicentini L. M., Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells. FEBS Letters 2000 481 3 271 276 2-s2.0-0034703361 10.1016/S0014-5793(00)02012-3
132. Florio T., Scorziello A., Thellung S., Salzano S., Berlingieri M. T., Fusco A., Schettini G., Oncogene transformation of PC Cl3 clonal thyroid cell line induces an autonomous pattern of proliferation that correlates with a loss of basal and stimulated phosphotyrosine phosphatase activity. Endocrinology 1997 138 9 3756 3763 2-s2.0-0030741982 10.1210/en.138.9.3756 (Pubitemid 27351926)
133. Massa A., Barbieri F., Aiello C., Arena S., Pattarozzi A., Pirani P., Corsaro A., Iuliano R., Fusco A., Zona G., Spaziante R., Florio T., Schettini G., The expression of the phosphotyrosine phosphatase DEP-1/PTP η dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation. The Journal of Biological Chemistry 2004 279 28 29004 29012 2-s2.0-3142748559 10.1074/jbc.M403573200 (Pubitemid 38915770)
134. Massa A., Barbieri F., Aiello C., Iuliano R., Arena S., Pattarozzi A., Corsaro A., Villa V., Fusco A., Zona G., Spaziante R., Schettini G., Florio T., The phosphotyrosine phosphatase η mediates somatostatin inhibition of glioma proliferation via the dephosphorylation of ERK1/2. Annals of the New York Academy of Sciences 2004 1030 264 274 2-s2.0-20144363057 10.1196/annals.1329.033 (Pubitemid 40378922)
135. Arena S., Pattarozzi A., Massa A., Esteve J. P., Iuliano R., Fusco A., Susini C., Florio T., An intracellular multi-effector complex mediates somatostatin receptor 1 activation of phospho-tyrosine phosphatase η Molecular Endocrinology 2007 21 1 229 246 2-s2.0-33845969497 10.1210/me.2006-0081 (Pubitemid 46041702)
136. Ferrante E., Pellegrini C., Bondioni S., Peverelli E., Locatelli M., Gelmini P., Luciani P., Peri A., Mantovani G., Bosari S., Beck-Peccoz P., Spada A., Lania A., Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocrine-Related Cancer 2006 13 3 955 962 2-s2.0-33751102699 10.1677/erc.1.01191 (Pubitemid 44767383)
137. Guillermet J., Saint-Laurent N., Rochaix P., Cuvillier O., Levade T., Schally A. V., Pradayrol L., Buscail L., Susini C., Bousquet C., Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2003 100 1 155 160 2-s2.0-0037422536 10.1073/pnas.0136771100 (Pubitemid 36078044)
138. 2 somatostatin and TNF α receptors to induce apoptosis: crosstalk between NF- B and JNK pathways. Cell Death and Differentiation 2007 14 2 197 208 2-s2.0-33846246279 10.1038/sj.cdd.4401939 (Pubitemid 46092223)
139. Sharma K., Srikant C. B., Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. International Journal of Cancer 1998 76 2 259 266 (Pubitemid 28180381)
140. Murray R. D., Kim K., Ren S. G., Chelly M., Umehara Y., Melmed S., Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. Journal of Clinical Investigation 2004 114 3 349 356 2-s2.0-4043058143 10.1172/JCI200419933 (Pubitemid 39071607)
141. Dasgupta P., Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacology and Therapeutics 2004 102 1 61 85 2-s2.0-1842471298 10.1016/j.pharmthera.2004.02.002 (Pubitemid 38429986)
142. Albini A., Florio T., Giunciuglio D., Masiello L., Carlone S., Corsaro A., Thellung S., Cai T., Noonan D. M., Schettini G., Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. The FASEB Journal 1999 13 6 647 655 2-s2.0-0032921982 (Pubitemid 29156396)
143. Florio T., Morini M., Villa V., Arena S., Corsaro A., Thellung S., Culler M. D., Pfeffer U., Noonan D. M., Schettini G., Albini A., Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 2003 144 4 1574 1584 2-s2.0-0037388747 10.1210/en.2002-220949 (Pubitemid 36428500)
144. Florio T., Arena S., Pattarozzi A., Thellung S., Corsaro A., Villa V., Massa A., Diana F., Spoto G., Forcella S., Damonte G., Filocamo M., Benatti U., Schettini G., Basic fibroblast growth factor activates endothelial nitric-oxide synthase in CHO-K1 cells via the activation of ceramide synthesis. Molecular Pharmacology 2003 63 2 297 310 2-s2.0-0037311268 10.1124/mol.63.2.297 (Pubitemid 36158365)
145. 2) regulate cGMP production in rat retina. Regulatory Peptides 2006 133 1-3 41 46 2-s2.0-29244465868 10.1016/j.regpep. 2005.09.034 (Pubitemid 41820334)
146. Pyronnet S., Bousquet C., Najib S., Azar R., Laklai H., Susini C., Antitumor effects of somatostatin. Molecular and Cellular Endocrinology 2008 286 1-2 230 237 2-s2.0-43549108138 10.1016/j.mce.2008.02.002
147. Saveanu A., Jaquet P., Somatostatin-dopamine ligands in the treatment of pituitary adenomas. Reviews in Endocrine and Metabolic Disorders 2009 10 2 83 90 2-s2.0-67349160224 10.1007/s11154-008-9086-0
148. Tateno T., Kato M., Tani Y., Oyama K., Yamada S., Hirata Y., Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocrine Journal 2009 56 4 579 584 2-s2.0-68449089018 10.1507/endocrj.K08E-186
149. Fusco A., Gunz G., Jaquet P., Dufour H., Germanetti A. L., Guller M. D., Barlier A., Saveanu A., Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. European Journal of Endocrinology 2008 158 5 595 603 2-s2.0-43149090261 10.1530/EJE-07-0806 (Pubitemid 351639596)
150. Saveanu A., Morange-Ramos I., Gunz G., Dufour H., Enjalbert A., Jaquet P., A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies. European Journal of Endocrinology 2001 145 1 35 41 2-s2.0-0034924296 (Pubitemid 32677674)
151. Yoshihara A., Isozaki O., Hizuka N., Nozoe Y., Harada C., Ono M., Kawamata T., Kubo O., Hori T., Takano K., Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting longterm response to octreotide therapy. Endocrine Journal 2007 54 1 133 138 2-s2.0-33947605750 10.1507/endocrj.K06-133 (Pubitemid 46481681)
152. 5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. The Journal of Clinical Endocrinology and Metabolism 2010 95 5 2497 2502 2-s2.0-77952763842 10.1210/jc.2009-2247
153. Taboada G. F., Luque R. M., Neto L. V., Machado E. D. O., Sbaffi B. C., Domingues R. C., Marcondes J. B., Chimelli L. M. C., Fontes R., Niemeyer P., de Carvalho D. P., Kineman R. D., Gadelha M. R., Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. European Journal of Endocrinology 2008 158 3 295 303 2-s2.0-40949154229 10.1530/EJE-07-0562 (Pubitemid 351404992)
154. Melmed S., Sternberg R., Cook D., Klibanski A., Chanson P., Bonert V., Vance M. L., Rhew D., Kleinberg D., Barkan A., A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. The Journal of Clinical Endocrinology and Metabolism 2005 90 7 4405 4410 2-s2.0-23044466974 10.1210/jc.2004-2466 (Pubitemid 41058228)
155. Danila D. C., Haidar J. N. S., Zhang X., Katznelson L., Culler M. D., Klibanski A., Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. The Journal of Clinical Endocrinology and Metabolism 2001 86 7 2976 2981 2-s2.0-0034922866 10.1210/jc.86.7.2976 (Pubitemid 32673451)
156. Resmini E., Dadati P., Ravetti J. L., Zona G., Spaziante R., Saveanu A., Jaquet P., Culler M. D., Bianchi F., Rebora A., Minuto F., Ferone D., Clinical case seminar: rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. The Journal of Clinical Endocrinology and Metabolism 2007 92 5 1592 1599 2-s2.0-34249856993 10.1210/jc.2006-2084 (Pubitemid 46997156)
157. Florio T., Thellung S., Arena S., Corsaro A., Spaziante R., Gussoni G., Acuto G., Giusti M., Giordano G., Schettini G., Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. European Journal of Endocrinology 1999 141 4 396 408 2-s2.0-0032706121 10.1530/eje.0.1410396 (Pubitemid 29529495)
158. Florio T., Thellung S., Corsaro A., Bocca L., Arena S., Pattarozzi A., Villa V., Massa A., Diana F., Schettini D., Barbieri F., Ravetti J. L., Spaziante R., Giusti M., Schettini G., Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clinical Endocrinology 2003 59 1 115 128 2-s2.0-0038095663 10.1046/j.1365-2265.2003.01811.x (Pubitemid 36774117)
159. 2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion. Molecular and Cellular Endocrinology 2012 355 1 106 113
160. de Bruin C., Pereira A. M., Feelders R. A., Romijn J. A., Roelfsema F., Sprij-Mooij D. M., Van Aken M. O., Van Lelij A. J. D., De Herder W. W., Lamberts S. W. J., Hofland L. J., Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. The Journal of Clinical Endocrinology and Metabolism 2009 94 4 1118 1124 2-s2.0-65249166135 10.1210/jc.2008-2101
161. van der Pas R., de Herder W. W., Hofland L., New developments in medical therapy of Cushing's syndrome. Endocrine-Related Cancer 2012 19 6 R205 R223
162. Hofland L. J., van der Hoek J., Feelders R., van Aken M. O., van Koetsveld P. M., Waaijers M., Sprij-Mooij D., Bruns C., Weckbecker G., de Herder W. W., Beckers A., Lamberts S. W. J., The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. European Journal of Endocrinology 2005 152 4 645 654 2-s2.0-20244376493 10.1530/eje.1.01876 (Pubitemid 40575811)
163. Boscaro M., Ludlam W. H., Atkinson B., Glusman J. E., Petersenn S., Reincke M., Snyder P., Tabarin A., Biller B. M. K., Findling J., Melmed S., Darby C. H., Hu K., Wang Y., Freda P. U., Grossman A. B., Frohman L. A., Bertherat J., Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. The Journal of Clinical Endocrinology and Metabolism 2009 94 1 115 122 2-s2.0-58149383820 10.1210/jc.2008-1008
164. Dalm V. A. S. H., Hofland L. J., Lamberts S. W. J., Future clinical prospects in somatostatin/cortistatin/somatostatin receptor field. Molecular and Cellular Endocrinology 2008 286 1-2 262 277 2-s2.0-43549093753 10.1016/j.mce.2007.09.005 (Pubitemid 351680236)
165. Gatto F., Barbieri F., Castelletti L., Arvigo M., Pattarozzi A., Annunziata F., Saveanu A., Minuto F., Castellan L., Zona G., Florio T., Ferone D., In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5. Pituitary 2011 14 2 141 147 2-s2.0-79958159811 10.1007/s11102-010-0271-2
166. Gatto F., Barbieri F., Gatti M., Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins. Clinical Endocrinology 2012 76 3 407 414
167. O'Toole D., Saveanu A., Couvelard A., Gunz G., Enjalbert A., Jaquet P., Ruszniewski P., Barlier A., The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. European Journal of Endocrinology 2006 155 6 849 857 2-s2.0-33845989087 10.1530/eje.1.02307 (Pubitemid 46040624)
168. Öberg K. E., Reubi J., Kwekkeboom D. J., Krenning E. P., Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010 139 3 742.e1 753.e1 2-s2.0-77956168244 10.1053/j.gastro.2010.07.002
169. Rinke A., Müller H. H., Schade-Brittinger C., Klose K. J., Barth P., Wied M., Mayer C., Aminossadati B., Pape U. F., Bläker M., Harder J., Arnold C., Gress T., Arnold R., Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. Journal of Clinical Oncology 2009 27 28 4656 4663 2-s2.0-70350442637 10.1200/JCO.2009.22.8510
170. Bousquet C., Lasfargues C., Chalabi M., Clinical review: current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy. The Journal of Clinical Endocrinology and Metabolism 2012 97 3 727 737
171. Mezo G., Manea M., Receptor-mediated tumor targeting based on peptide hormones. Expert Opinion on Drug Delivery 2010 7 1 79 96 2-s2.0-73649137902 10.1517/17425240903418410
172. Dizeyi N., Konrad L., Bjartell A., Wu H., Gadaleanu V., Hansson J., Helboe L., Abrahamsson P. A., Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urologic Oncology 2002 7 3 91 98 2-s2.0-0036237190 10.1016/S1078-1439(01)00173-9
173. Kosari F., Munz J. M. A., Savci-Heijink C. D., Spiro C., Klee E. W., Kube D. M., Tillmans L., Slezak J., Karnes R. J., Cheville J. C., Vasmatzis G., Identification of prognostic biomarkers for prostate cancer. Clinical Cancer Research 2008 14 6 1734 1743 2-s2.0-41549090588 10.1158/1078-0432.CCR-07-1494 (Pubitemid 351469458)
174. Lattanzio L., Tonissi F., Monteverde M., Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells. Anticancer Drugs 2012 24 2 120 130
175. Lo Nigro C., Maffi M., Fischel J. L., Formento P., Milano G., Merlano M., The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data. BJU International 2008 102 5 622 627 2-s2.0-48749111500 10.1111/j.1464-410X.2008. 07706.x
176. Schally A. V., Engel J. B., Emons G., Block N. L., Pinski J., Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors. Current Drug Delivery 2011 8 1 11 25 2-s2.0-78650873834 10.2174/156720111793663598
177. Friedlander T. W., Weinberg V. K., Small E. J., SharibB S. J., Harzstark A. L., Lin A. M., Fong L., Ryan C. J., Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urologic Oncology 2012 30 4 408 414 2-s2.0-77957116505 10.1016/j.urolonc.2010.06.014
178. Koutsilieris M., Mitsiades C. S., Bogdanos J., Dimopoulos T., Karamanolakis D., Milathianakis C., Tsintavis A., Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clinical Cancer Research 2004 10 13 4398 4405 2-s2.0-3042851917 10.1158/1078-0432.CCR-04-0077 (Pubitemid 38878880)
179. Mitsiades C. S., Bogdanos J., Karamanolakis D., Milathianakis C., Dimopoulos T., Koutsilieris M., Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate versus zoledronate in patients with androgen ablation-refractory prostate cancer. Anticancer Research 2006 26 5B 3693 3700 2-s2.0-33750700455 (Pubitemid 44701445)
180. Kumar U., Grigorakis S. I., Watt H. L., Sasi R., Snell L., Watson P., Chaudhari S., Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1-5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Research and Treatment 2005 92 2 175 186 2-s2.0-21644450897 10.1007/s10549-005-2414-0 (Pubitemid 40933583)
181. Pagliacci M. C., Tognellini R., Grignani F., Nicoletti I., Inhibition of human breast cancer cell (MCF-7) growth in vitro by the somatostatin analog SMS 201-995: effects on cell cycle parameters and apoptotic cell death. Endocrinology 1991 129 5 2555 2562 2-s2.0-0025719564
182. Prevost G., Foehrle E., Thomas F., Pihan I., Veber N., Starzec A., Israel L., Growth of human breast cancer cell lines is inhibited by the somatostatin analog BIM23014. Endocrinology 1991 129 1 323 329 2-s2.0-0025873494
183. Weckbecker G., Liu R., Tolcsvai L., Bruns C., Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Research 1992 52 18 4973 4978 2-s2.0-0026787323
184. 5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells. Oncogene 2012 31 16 2049 2061
185. Shi R., Yu H., McLarty J., Glass J., IGF-I and breast cancer: a meta-analysis. International Journal of Cancer 2004 111 3 418 423 2-s2.0-3242884950 10.1002/ijc.20233 (Pubitemid 38998824)
186. Kleinberg D. L., Wood T. L., Furth P. A., Lee A. V., Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocrine Reviews 2009 30 1 51 74 2-s2.0-57149143868 10.1210/er.2008-0022
187. Ruan W., Fahlbusch F., Clemmons D. R., Monaco M. E., Walden P. D., Silva A. P., Schmid H. A., Kleinberg D. L., SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3? Molecular Endocrinology 2006 20 2 426 436 2-s2.0-31444447551 10.1210/me.2005-0283 (Pubitemid 43152515)
188. Kleinberg D. L., Ameri P., Singh B., Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia. Pituitary 2011 14 1 44 52 2-s2.0-79951958341 10.1007/s11102-010-0257-0
189. Canobbio L., Cannata D., Miglietta L., Boccardo F., Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels. Anticancer Research 1995 15 6B 2687 2690 2-s2.0-0029551831 (Pubitemid 26095083)
190. Ingle J. N., Suman V. J., Kardinal C. G., A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 1999 85 6 1284 1292 (Pubitemid 29125081)
191. Dolan J. T., Miltenburg D. M., Granchi T. S., Miller C. C., Brunicardi F. C., Treatment of metastatic breast cancer with somatostatin analogues-a meta-analysis. Annals of Surgical Oncology 2001 8 3 227 233 2-s2.0-0035069931 10.1245/aso.2001.8.3.227 (Pubitemid 32294803)
192. Bajetta E., Procopio G., Ferrari L., Martinetti A., Zilembo N., Catena L., Alú M., Della Torre S., Alberti D., Buzzoni R., A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer 2002 94 2 299 304 2-s2.0-0037080274 10.1002/cncr.10239 (Pubitemid 34081357)
193. Helle S. I., Mietlowski W., Guastalla J. P., Szakolczai I., Bajetta E., Sommer H., Baltali E., Pinter T., Csepreghy M., Ottestad L., Boni C., Bryce C., Klijn J. G. M., Lønning P. E., Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy. European Journal of Cancer 2005 41 5 694 701 2-s2.0-20044384178 10.1016/j.ejca.2004.12.015 (Pubitemid 40342551)
194. Sommer H., Pröhl-Steimer B., Bajetta E., Haus U., Janni W., Kay A., A randomized, double-blind, placebo-controlled, phase 3 trial comparing SMS 201-995 pa LAR plus tamoxifen versus tamoxifen plus placebo in women with locally recurrent or metastatic breast cancer. Zentralblatt fur Gynakologie 2001 123 10 557 561 2-s2.0-0035199903 10.1055/s-2001-19088 (Pubitemid 33115624)
195. Pritchard K. I., Shepherd L. E., Chapman J. A., Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA. 14. Journal of Clinical Oncology 2011 29 29 3869 3876
196. Vuaroqueaux V., Dutour A., Bourhim N., Ouafik L. H., Monges G., Briard N., Sauze N., Oliver C., Grino M., Increased expression of the mRNA encoding the somatostatin receptor subtype five in human colorectal adenocarcinoma. Journal of Molecular Endocrinology 2000 24 3 397 408 2-s2.0-0034122349 (Pubitemid 30415014)
197. Qiu C. Z., Zhu S. Z., Wu Y. Y., Wang C., Huang Z. X., Qiu J. L., Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer. World Journal of Gastroenterology 2006 12 13 2011 2015 2-s2.0-33646444794
198. Bläker M., Schmitz M., Gocht A., Burghardt S., Schulz M., Bröring D. C., Pace A., Greten H., De Weerth A., Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. Journal of Hepatology 2004 41 1 112 118 2-s2.0-3442880408 10.1016/j.jhep.2004.03.018 (Pubitemid 39005161)
199. Szepeshazi K., Schally A. V., Nagy A., Wagner B. W., Bajo A. M., Halmos G., Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. Cancer 2003 98 7 1401 1410 2-s2.0-0141675107 10.1002/cncr.11649 (Pubitemid 37151494)
200. Palmieri G., Montella L., Aiello C., Barbieri F., Di Vizio D., Schulz S., Beninati S., Budillon A., Caraglia M., Insabato L., Florio T., Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract. Amino Acids 2007 32 3 395 400 2-s2.0-34147138843 10.1007/s00726-006-0386-y (Pubitemid 46559578)
201. Florio T., Montella L., Corsaro A., De Chiara A., Apice G., Fazioli F., Lastoria S., Schettini G., Palmieri G., In vitro and in vivo expression of somatostatin receptors in intermediate and malignant soft tissue tumors. Anticancer Research 2003 23 3B 2465 2471 2-s2.0-0042807618 (Pubitemid 36897116)
202. Colucci R., Blandizzi C., Ghisu N., Florio T., Del Tacca M., Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation. British Journal of Pharmacology 2008 155 2 198 209 2-s2.0-51349149417 10.1038/bjp.2008.268
203. Cascinu S., del Ferro E., Catalano G., A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. British Journal of Cancer 1995 71 1 97 101 2-s2.0-0028878559
204. Goldberg R. M., Moertel C. G., Wieand H. S., A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. North Central Cancer Treatment Group and the Mayo Clinic. Cancer 1995 76 6 961 966
205. Hua Y. P., Yin X. Y., Peng B. G., Li S. Q., Lai J. M., Liang H. Z., Liang L. J., Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma. Chemotherapy 2009 55 5 312 320 2-s2.0-67649859237 10.1159/000227763
206. Xie Y., Chen S., Wang C. H., Tang C. W., Induction of necrosis in the hepatocellular carcinoma HepG2 xenografts treated with SOM230. Zhonghua Gan Zang Bing Za Zhi 2009 17 10 759 764 2-s2.0-79951980619
207. Prete S. D., Montella L., Caraglia M., Maiorino L., Cennamo G., Montesarchio V., Piai G., Febbraro A., Tarantino L., Capasso E., Palmieri G., Guarrasi R., Bianco M., Mamone R., Savastano C., Pisano A., Vincenzi B., Sabia A., D'Agostino A., Faiola V., Addeo R., Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemotherapy and Pharmacology 2010 66 5 837 844 2-s2.0-77956228586 10.1007/s00280-009-1226-z
208. Barbare J. C., Bouché O., Bonnetain F., Dahan L., Lombard-Bohas C., Faroux R., Raoul J. L., Cattan S., Lemoine A., Blanc J. F., Bronowicki J. P., Zarski J. P., Cazorla S., Gargot D., Thevenot T., Diaz E., Bastie A., Aparicio T., Bedenne L., Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. European Journal of Cancer 2009 45 10 1788 1797 2-s2.0-67149113508 10.1016/j.ejca.2009.02.018
209. Jackson K., Soutto M., Peng D., Epigenetic silencing of somatostatin in gastric cancer. Digestive Diseases and Sciences 2011 56 1 125 130
210. Gao S., Yu B. P., Li Y., Dong W. G., Luo H. S., Antiproliferative effect of octreotide on gastric cancer cells mediated by inhibition of Akt/PKB and telomerase. World Journal of Gastroenterology 2003 9 10 2362 2365 2-s2.0-0142151220 (Pubitemid 37321481)
211. Tang C., Liu C., Zhou X., Wang C., Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer. International Journal of Cancer 2004 112 3 470 474 2-s2.0-6344283034 10.1002/ijc.20256 (Pubitemid 39390613)
212. Huang M. T., Chen Z. X., Wei B., Zhang B., Wang C. H., Huang M. H., Liu R., Tang C. W., Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide. Acta Pharmacologica Sinica 2007 28 11 1842 1850 2-s2.0-35648976650 10.1111/j.1745-7254.2007.00652.x (Pubitemid 350029325)
213. Zhao B., Yang P., Yang J., A randomized trial of somatostatin to regulate the VEGFs/VEGFRs in patients with gastric cancer. Hepatogastroenterology 2011 58 109 1425 1430
214. Held-Feindt J., Krisch B., Forstreuter F., Mentlein R., Somatostatin receptors in gliomas. Journal of Physiology Paris 2000 94 3-4 251 258 2-s2.0-0033737942 10.1016/S0928-4257(00)00213-8
215. Lamszus K., Meyerhof W., Westphal M., Somatostatin and somatostatin receptors in the diagnosis and treatment of gliomas. Journal of Neuro-Oncology 1997 35 3 353 364 2-s2.0-0030829688 10.1023/A:1005893223090 (Pubitemid 27511138)
216. Cattaneo M. G., Gentilini D., Vicentini L. M., Deregulated human glioma cell motility: inhibitory effect of somatostatin. Molecular and Cellular Endocrinology 2006 256 1-2 34 39 2-s2.0-33746878815 10.1016/j.mce.2006.05.006 (Pubitemid 44189707)
217. Grobben B., de Deyn P. P., Slegers H., Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell and Tissue Research 2002 310 3 257 270 2-s2.0-1842867380 10.1007/s00441-002-0651-7 (Pubitemid 35435769)
218. Barbieri F., Florio T., Characterization of the differential efficiacy of somatostatin receptor agonists in the inhibition of the growth of experimental gliomas and identification of the intracellular mechanisms involved. European Journal of Clinical and Medical Oncology 2011 3 3 46 53 2-s2.0-79960105189
219. Reubi J. C., Maurer R., Klijn J. G. M., High incidence of somatostatin receptors in human meningiomas: biochemical characterization. The Journal of Clinical Endocrinology and Metabolism 1986 63 2 433 438 2-s2.0-0022506055 (Pubitemid 16035694)
220. Arena S., Barbieri F., Thellung S., Pirani P., Corsaro A., Villa V., Dadati P., Dorcaratto A., Lapertosa G., Ravetti J. L., Spaziante R., Schettini G., Florio T., Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. Journal of Neuro-Oncology 2004 66 1-2 155 166 2-s2.0-10744220120 10.1023/B:NEON.0000013498. 19981.55 (Pubitemid 38258370)
221. Chamberlain M. C., The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma. Current Opinion in Oncology 2012 24 6 666 671
222. Chamberlain M. C., Glantz M. J., Fadul C. E., Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 2007 69 10 969 973 2-s2.0-34548444537 10.1212/01.wnl.0000271382.62776.b7 (Pubitemid 47366049)